Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SAN DIEGO, June 01, 2017 -- Daré Bioscience, Inc., a privately-held, clinical-stage healthcare company advancing products for women's reproductive health, today announced that Sabrina Martucci Johnson, Daré Founder and CEO, will present at the LD Micro Invitational Conference on Wednesday, June 7, 2017, at 7:30 a.m. PST at the Luxe Sunset Bel Air Hotel in Los Angeles, California.
“Daré’s product candidate, Ovaprene®, is a clinical stage, non-hormonal contraceptive ring for monthly use,” said Ms. Johnson. “Since the approval of the birth control pill by the FDA in 1960, most innovation has focused on hormones. If approved, Ovaprene would address an unmet need because it is a non-hormonal monthly option. The only contraceptive ring on the market is a hormonal contraceptive ring, NuvaRing®, with 2016 sales of $777 million.”
About Daré Bioscience
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. Daré believes there is an unmet need in the United States, in other developed countries, and in developing countries, for innovative product candidates that expand options, improve outcomes and are easy to use. Product development in women's reproductive health is fragmented, creating a potential opportunity for Daré. Daré’s goal is to fill the gap by taking products from innovation through development. The Daré team is well-suited to ensure these products advance and are one day commercially available. The founders bring experience in global women's healthcare as well as success in prior ventures in funding, achieving regulatory approvals, partnering, and launching a number of products, including devices, therapeutics and diagnostics.
For more information on Daré, please visit www.darebioscience.com.
Contact: Sabrina Johnson 858-769-9145 [email protected]
